RSS Feeds
High-Output Heart Failure Associated with Anagrelide Therapy for Essential Thrombocytosis
- Peter J. Engel, MD;
- Heide Johnson, RN;
- Robert P. Baughman, MD; and
- Arthur I. Richards, MD
- From The Ohio Heart Health Center and The Lindner Center for Research and Education, Cincinnati, OH 45219; University of Cincinnati Medical Center, Cincinnati, OH 45267; and Oncology Hematology Care, Inc., Cincinnati, OH 45219.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Congestive heart failure (CHF) is usually associated with disorders causing low cardiac output; disorders associated with high cardiac output rarely cause CHF (1, 2). Medications have not previously been thought to cause high-output heart failure. New-onset CHF and cardiovascular death have rarely been associated with therapy with anagrelide (3-5), a novel treatment for essential thrombocytosis. The mechanism of cardiac dysfunction related to anagrelide has not previously been reported.
Objective: To report a case of high-output heart failure …
This 100-word excerpt has been provided in the absence of an abstract.
